Alpha Fusion, a cancer therapy drug research startup, raised 450 million yen in their latest funding round.

‍

Alpha Fusion is a startup researching new cancer treatments through the Japan Science and Technology Agency’s Joint Research Promotion Program, an industry-academia program in which Osaka University, RIKEN, and several other research institutes and companies participate.

‍

Alpha Fusion's Targeted Alpha Therapy (TAT) is a method of administering a drug that physically destroys cancer cells with alpha rays, and is expected to achieve a surgical-like effect despite being administered as a drug.

‍

Source: https://prtimes.jp/main/html/rd/p/000000004.000091191.html

‍